HER-2/neu-targeting gene therapy-a review

Gene

Volumn 159, Issue 1, 1995, Pages 65-71

  Hung, Mien Chie ^a   Matin, Angabin ^a   Zhang, Yujiao ^a   Xing, Xiangming ^a   Sorgi, Frank ^b   Huang, Leaf ^b   Yu, Dihua ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

adenovirus vector; c erbB 2; E1A; large T; Liposome; oncogene

Indexed keywords

GENE PRODUCT; LIPOSOME; T ANTIGEN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENOVIRUS; CANCER THERAPY; CONFERENCE PAPER; EPIDEMIOLOGY; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC TRANSCRIPTION; HUMAN; MUTANT; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; THERAPY; TUMOR GROWTH;

ADENOVIRIDAE; ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; GENE THERAPY; GENES, ERBB-2; GENETIC VECTORS; HUMAN; LIPOSOMES; NEOPLASMS; SUPPORT, U.S. GOV'T, P.H.S.;

ADENOVIRIDAE; ANIMALIA; HUMAN ADENOVIRUS TYPE 5;

EID: 0029065583     PISSN: 03781119     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-1119(94)00459-6     Document Type: Article

References (84)

1. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene
2. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185
3. The neu oncogene encodes an epidermal growth factor receptor-related protein
4. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer
5. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease
6. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading
7. Receptors for hormones and growth factors and onco-gene amplification in human ovarian cancer
8. Mechanism of epidermal growth factor receptor autophosphorylation and high-affinity binding
9. Cancer Statistics. 1992
10. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene
11. Tyrosine kinase receptor with extensive homology to the EGF receptor shares chromosomal location with the neu oncogene
12. Screening in ovarian cancer
13. Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon
14. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells
15. Characterization of a neu/c-erbB-2 protein-specific activating factor
16. Prediction of similar transforming regions in simian virus 40 large T, adenovirus Ela, and myc oncoproteins
17. p53 and DNA polymerase a compete for binding to SV40 large T antigen
18. A novel cationic liposome reagent for efficient transfection of mammalian cells
19. Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism
20. prognostic importance of c-erbB-2 expression in breast cancer
21. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease
22. A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB2 in mammary tumor lines
23. Identification of heregulin, a specific activator of p185erbB2
24. Oral cancer progression of the C-erbB-2/neu proto-oncogene in ovarian cancer
25. Structure and inducible regulation of the human c-erb B2/neu promoter
26. Increased expression of the putative growth factor receptor p185 HER-2 causes transformation and tumorigenesis of NIH-3T3 cells
27. Molecular cloning of the neu gene: absence of gross structural alterations in oncogeneic alleles
28. Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation
29. Aberrant expression of the C-erbB-2/neu protooncogene in ovarian cancer
30. In vitro mutagenesis of a putative DNA binding domain of SV40 large T
31. Mutations in transmembrane domain of c-erbB-2 gene in human malignant tumors of the central nervous system
32. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms
33. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
34. Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer
35. erb2
36. Negative regulation of the neu promoter by the SV40 large T antigen
37. The retinoblastoma gene product, Rb, represses neu expression through two regions within the neu regulatory sequence
38. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer
39. HER-2/neu overexpression counteracts the growth effects of c-myc in breast cancer cells
40. Mechanism of deregulated HER-2/neu expression in breast cancer cell lines
41. ERBB-2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix
42. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene
43. Early mutation of the neu (c-erbB-2) gene during ethylnitrosourea-induced oncogenesis in the rat Schwann cell lineage
44. Expression of the c-erbB2 gene in the BT474 human mammary tumor cell line: measurement of the c-erbB2 mRNA half-life
45. Amplification, overexpression, and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas
46. Isolation of the Neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells
47. Epidemiology and etiology of ovarian cancer
48. Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor
49. c-neu density govern receptor interactions and tyrosine kinase activation
50. Direct sequencing analysis of transmembrane region of human neu gene by polymerase chain reaction
51. The neu gene: An erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor
52. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer
53. Detection of the ligand activity of the c-erbB-2 protein in calf serum
54. Overexpression of the C-erbB-2/neu-encoded p185 protein in primary lung cancer
55. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
56. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
57. Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo
58. Multiple cis-and trans-acting elements involved in regulation of the neu gene
59. c-myc reverses neu-induced transformated morphology by transcriptional repression
60. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up
61. DNA tumor viruses
62. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations
63. Expression and amplification of the HER-2/neu (c-erb-2) protooncogene in epithelial ovarian tumors and cell lines
64. Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene
65. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function
66. A point mutation in the neu oncogeen mimics ligand induction of receptor aggregation
67. Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung
68. Neu differentiation factor: a transmemebrane glycoprotein containing an EGF domain and an immunoglobulin homology unit
69. Cloning and characterization of the mouse neu promoter
70. Similarity of protein encoded by the human c-erbB-2 gene to the epidermal growth factor receptor
71. Repressed expression of the HER-2/c-erbB-2 proto-oncogene by the adenovirus Ela gene products
72. Identification and characterization of a novel enhancer for the rat neu promoter
73. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue
74. Correlation of c-erbB-2 protein expression and lymph node status in early gastric cancer
75. Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells
76. Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products
77. Adenovirus type 5 Ela gene products act as transformation suppressors of the neu oncogene
78. Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products
79. The retinoblastoma gene product suppresses neu oncogene-induced transformation via transcriptional repression of neu
80. Enhanced C-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A
81. C-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties
82. Low metastatic potential of clone from murine colon adenocarcinoma 26 increased by transfection of activated c-erbB-2 gene
83. Amplification and rearrangement of c-erbB proto-oncogenes in cancer of human female genital tract
84. Negative autoregulation of the neu gene is mediated by a novel enhancer